Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Adamo, V"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-9 z 9
    Tytuł:
    High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.
    Autorzy:
    Cortellini A; Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy. .; Division of Cancer, Department of Surgery and Cancer, ICTEM Building, Hammersmith Hospital, Imperial College London, Du Cane Road, London, W12 0HS, UK. .
    Giusti R; Medical Oncolgy, St. Andrea Hospital, Rome, Italy.
    Filetti M; Medical Oncolgy, St. Andrea Hospital, Rome, Italy.
    Citarella F; Medical Oncology, Campus Bio-Medico University, Rome, Italy.
    Adamo V; Medical Oncology, A.O. Papardo and Department of Human Pathology, University of Messina, Messina, Italy.
    Santini D; Medical Oncology, Campus Bio-Medico University, Rome, Italy.
    Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
    Nigro O; Medical Oncology, ASST-Sette Laghi, Varese, Italy.
    Cantini L; Department of Pulmonary Diseases, Erasmus Medical Center, Rotterdam, The Netherlands.; Oncology Clinic, Università Politecnica Delle Marche, Ospedali Riuniti Di Ancona, Ancona, Italy.
    Di Maio M; Department of Oncology, University of Turin and Medical Oncology, AO Ordine Mauriziano, Turin, Italy.
    Aerts JGJV; Department of Pulmonary Diseases, Erasmus Medical Center, Rotterdam, The Netherlands.
    Bria E; Comprehensive Cancer Center, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy.; Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Romae, Lazio, Italy.
    Bertolini F; Dipartimeto Di Oncologia Ed Ematologia, AOU Policlinico Modena, Modena, Italy.
    Ferrara MG; Comprehensive Cancer Center, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy.; Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Romae, Lazio, Italy.
    Ghidini M; Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
    Grossi F; Division of Medical Oncology, University of Insubria, Varese, Italy.
    Guida A; Struttura Complessa Di Oncologia Medica E Traslazionale, Azienda Ospedaliera Santa Maria Di Terni, Terni, Italy.
    Berardi R; Oncology Clinic, Università Politecnica Delle Marche, Ospedali Riuniti Di Ancona, Ancona, Italy.
    Morabito A; Thoracic Medical Oncology, Istituto Nazionale Tumori 'Fondazione G Pascale', IRCCS, Napoli, Italy.
    Genova C; UOC Clinica Di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.; Dipartimento Di Medicina Interna E Specialità Mediche, Università Degli Studi Di Genova, Genoa, Italy.
    Mazzoni F; Department of Oncology, Careggi University Hospital, Florence, Italy.
    Antonuzzo L; Department of Oncology, Careggi University Hospital, Florence, Italy.
    Gelibter A; Medical Oncology (B), Policlinico Umberto I, 'Sapienza' University of Rome, Rome, Italy.
    Marchetti P; Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
    Chiari R; Medical Oncology, Ospedali Riuniti Padova Sud 'Madre Teresa Di Calcutta', Monselice, Italy.
    Macerelli M; Department of Oncology, University Hospital Santa Maria Della Misericordia, Udine, Italy.
    Rastelli F; Medical Oncology, Fermo Area Vasta 4, Fermo, Italy.
    Della Gravara L; Pneumo-Oncology Unit, Monaldi Hospital, Naples, Italy.
    Gori S; Oncology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, VR, Italy.
    Tuzi A; Medical Oncology, ASST-Sette Laghi, Varese, Italy.
    De Tursi M; Dipartimento Di Terapie Innovative in Medicina E Odontoiatria, Università G. D'Annunzio, Chieti-Pescara, Chieti, Italy.
    Di Marino P; Clinical Oncology Unit, S.S. Annunziata Hospital, Chieti, Italy.
    Mansueto G; Medical Oncology, F. Spaziani Hospital, Frosinone, Italy.
    Pecci F; Oncology Clinic, Università Politecnica Delle Marche, Ospedali Riuniti Di Ancona, Ancona, Italy.
    Zoratto F; Medical Oncology, Santa Maria Goretti Hospital, Latina, Italy.
    Ricciardi S; Pneumo-Oncology Unit, St. Camillo-Forlanini Hospital, Rome, Italy.
    Migliorino MR; Pneumo-Oncology Unit, St. Camillo-Forlanini Hospital, Rome, Italy.
    Passiglia F; Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, TO, Italy.
    Metro G; Department of Medical Oncology, Santa Maria Della Misericordia Hospital, Azienda Ospedaliera Di Perugia, Perugia, Italy.
    Spinelli GP; UOC Territorial Oncology, AUSL Latina - CdS Aprilia, Aprilia, Italy.
    Banna GL; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
    Friedlaender A; Oncology Department, University Hospital of Geneva, Geneva, Switzerland.
    Addeo A; Oncology Department, University Hospital of Geneva, Geneva, Switzerland.
    Ficorella C; Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
    Porzio G; Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
    Tiseo M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy.
    Russano M; Medical Oncology, Campus Bio-Medico University, Rome, Italy.
    Russo A; Medical Oncology, A.O. Papardo and Department of Human Pathology, University of Messina, Messina, Italy.
    Pinato DJ; Division of Cancer, Department of Surgery and Cancer, ICTEM Building, Hammersmith Hospital, Imperial College London, Du Cane Road, London, W12 0HS, UK.; Department of Translational Medicine, Università del Piemonte Orientale 'A. Avogadro', Novara, Italy.
    Pokaż więcej
    Źródło:
    Journal of hematology & oncology [J Hematol Oncol] 2022 Jan 21; Vol. 15 (1), pp. 9. Date of Electronic Publication: 2022 Jan 21.
    Typ publikacji:
    Letter; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Immunotherapy*
    Carcinoma, Non-Small-Cell Lung/*therapy
    Lung Neoplasms/*therapy
    Carcinoma, Non-Small-Cell Lung/genetics ; DNA Damage ; Female ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Lung Neoplasms/genetics ; Male ; Treatment Outcome
    Raport
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort.
    Autorzy:
    Santini D; Medical Oncology, Campus Bio-Medico University, Rome, Italy.
    Zeppola T; Medical Oncology, Campus Bio-Medico University, Rome, Italy.
    Russano M; Medical Oncology, Campus Bio-Medico University, Rome, Italy.
    Citarella F; Medical Oncology, Campus Bio-Medico University, Rome, Italy.
    Anesi C; Medical Oncology, Campus Bio-Medico University, Rome, Italy.
    Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
    Tucci M; Medical Oncology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy.; National Cancer Research Center, Tumori Institute IRCCS Giovanni PaoloII, Bari, Italy.
    Russo A; Medical Oncology, A.O. Papardo & Department of Human Pathology, University of Messina, Messina, Italy.
    Sergi MC; Medical Oncology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy.
    Adamo V; Medical Oncology, A.O. Papardo & Department of Human Pathology, University of Messina, Messina, Italy.
    Stucci LS; Medical Oncology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy.
    Bersanelli M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy.
    Mazzaschi G; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
    Spagnolo F; IRCCS Ospedale Policlinico San Martino, Genova, Italy.
    Rastelli F; UOC Oncologia Ascoli Piceno - San Benedetto del Tronto, Area Vasta 5, ASUR Marche, Ancona, Italy.
    Giorgi FC; UOC Oncologia Ascoli Piceno - San Benedetto del Tronto, Area Vasta 5, ASUR Marche, Ancona, Italy.
    Giusti R; Medical Oncology Unit, Sant' Andrea Hospital of Rome, Rome, Italy.
    Filetti M; Medical Oncology Unit, Sant' Andrea Hospital of Rome, Rome, Italy.
    Marchetti P; Medical Oncology Unit, Sant' Andrea Hospital of Rome, Rome, Italy.; Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.; Medical Oncology (B), Policlinico Umberto I, 'Sapienza' University of Rome, Rome, Italy.
    Botticelli A; Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.; Medical Oncology (B), Policlinico Umberto I, 'Sapienza' University of Rome, Rome, Italy.
    Gelibter A; Medical Oncology (B), Policlinico Umberto I, 'Sapienza' University of Rome, Rome, Italy.
    Siringo M; Medical Oncology (B), Policlinico Umberto I, 'Sapienza' University of Rome, Rome, Italy.
    Ferrari M; Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
    Marconcini R; Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
    Vitale MG; Medical Oncology, University Hospital of Modena, Modena, Italy.
    Nicolardi L; UOC Oncologia Padova Sud - AULSS6 Euganea, Padova, Italy.
    Chiari R; UOC Oncologia Padova Sud - AULSS6 Euganea, Padova, Italy.
    Ghidini M; Medical Oncology Unit, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, Italy.
    Nigro O; Medical Oncology, ASST Sette Laghi, Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
    Grossi F; Division of Medical Oncology, University of Insubria, Varese, Italy.
    De Tursi M; Department of Medical, Oral & Biotechnological Sciences, University G. D'Annunzio, Chieti-Pescara, Italy.
    Di Marino P; Clinical Oncology Unit, S.S. Annunziata Hospital, Chieti, Italy.
    Pala L; Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy.
    Queirolo P; Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy.
    Bracarda S; S.C. Medical Oncology, Azienda Ospedaliera S. Maria, Terni, Italy.
    Macrini S; S.C. Medical Oncology, Azienda Ospedaliera S. Maria, Terni, Italy.
    Gori S; Oncology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, VR, Italy.
    Inno A; Oncology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, VR, Italy.
    Zoratto F; Medical Oncology, Santa Maria Goretti Hospital, Latina, Italy.
    Tanda ET; IRCCS Ospedale Policlinico San Martino, Genova, Italy.; Genetics of Rare Cancers, Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.
    Mallardo D; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori-IRCCS Fondazione 'G. Pascale', Naples, Italy.
    Vitale MG; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori-IRCCS Fondazione 'G. Pascale', Naples, Italy.
    Talbot T; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK.
    Ascierto PA; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori-IRCCS Fondazione 'G. Pascale', Naples, Italy.
    Pinato DJ; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK.; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
    Ficorella C; Medical Oncology Unit, St. Salvatore Hospital, L'Aquila, Italy.; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
    Porzio G; Medical Oncology Unit, St. Salvatore Hospital, L'Aquila, Italy.
    Cortellini A; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK. .; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy. .
    Pokaż więcej
    Źródło:
    Journal of translational medicine [J Transl Med] 2021 Jun 24; Vol. 19 (1), pp. 270. Date of Electronic Publication: 2021 Jun 24.
    Typ publikacji:
    Journal Article; Multicenter Study
    MeSH Terms:
    B7-H1 Antigen*
    Lung Neoplasms*/drug therapy
    Humans ; Immune Checkpoint Inhibitors ; Italy ; Programmed Cell Death 1 Receptor
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
    Autorzy:
    Bon G; Cellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. .
    Pizzuti L; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
    Laquintana V; Pathology Department, IRCCS Regina Elena National CancerInstitute, Rome, Italy.
    Loria R; Cellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
    Porru M; Area of Translational Research, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
    Marchiò C; Department of Medical Sciences, University of Turin, Turin, Italy.; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
    Krasniqi E; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy. .
    Barba M; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
    Maugeri-Saccà M; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
    Gamucci T; Medical Oncology, Sandro Pertini Hospital, Rome, Italy.
    Berardi R; Oncology Clinic, 'Ospedali Riuniti di Ancona' Hospital, Ancona, Italy.
    Livi L; Radiotherapy Unit, Department of Oncology, Careggi University Hospital, Florence, Italy.
    Ficorella C; Medical Oncology Unit, St Salvatore Hospital, L'Aquila, Italy.
    Natoli C; Department of Medical, Oral and Biotechnological Sciences, University Gabriele D'Annunzio, Chieti, Italy.
    Cortesi E; Department of Medical Oncology, University La Sapienza, Rome, Italy.
    Generali D; Breast Cancer Unit, ASST Cremona, Cremona, Italy.
    La Verde N; Oncology Unit, ASST Fatebenefratelli Sacco-PO Fatebenefratelli, Milan, Italy.
    Cassano A; Oncology Unit, IRCCS Foundation Polyclinic University A. Gemelli, University Cattolica Del Sacro Cuore, Rome, Italy.
    Bria E; Oncology Unit, IRCCS Foundation Polyclinic University A. Gemelli, University Cattolica Del Sacro Cuore, Rome, Italy.; University of Verona, Verona, Italy.
    Moscetti L; Department of Oncology and Hematology, University Hospital, Modena, Italy.
    Michelotti A; UO Medical Oncology, S. Chiara Hospital, Pisa, Italy.
    Adamo V; Medical Oncology Unit, A.O. Papardo & Department of Human Pathology, University of Messina, Messina, Italy.
    Zamagni C; Medical Oncology Unit, Addarii Institute of Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy.
    Tonini G; Department of Oncology, University Campus Biomedico, Rome, Italy.
    Barchiesi G; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
    Mazzotta M; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
    Marinelli D; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.; Medical Oncology Unit, Sant'Andrea University Hospital, Rome, Italy.
    Tomao S; Department of Radiological, Oncological and Anatomo-Pathological Sciences, University La Sapienza, Umberto I University Hospital, Rome, Italy.
    Marchetti P; Department of Medical Oncology, University La Sapienza, Rome, Italy.; Medical Oncology Unit, Sant'Andrea University Hospital, Rome, Italy.
    Valerio MR; Medical Oncology, Paolo Giaccone University Hospital, Palermo, Italy.
    Mirabelli R; Department of Ematology & Oncology, Pugliese-Ciaccio Hospital, Catanzaro, Italy.
    Russo A; Medical Oncology, Paolo Giaccone University Hospital, Palermo, Italy.
    Fabbri MA; Medical Oncology Unit, Belcolle Hospital, Viterbo, Italy.
    D'Ostilio N; Medical Oncology Unit, Lanciano-Vasto, Chieti, Italy.
    Veltri E; Medical Oncology Unit, Santa Maria Goretti Hospital, Latina, Italy.
    Corsi D; Medical Oncology Unit, Fatebenefratelli Hospital, Rome, Italy.
    Garrone O; Medical Oncology AO S. Croce and Carle Teaching Hospital, Cuneo, Italy.
    Paris I; Gynaecology - Oncology Unit, University Cattolica del Sacro Cuore, Rome, Italy.
    Sarobba G; Department of Medical Oncology, ASL Nuro, Nuoro, Italy.
    Giotta F; Department of Medical Oncology, IRCCS Giovanni Paolo II, Bari, Italy.
    Garufi C; Division of Medical Oncology, Pescara Hospital, Pescara, Italy.
    Cazzaniga M; Research Unit Phase I Trials and Oncology Unit, ASST, Monza, Italy.
    Del Medico P; Division of Medical Oncology, Reggio Calabria General Hospital, Reggio Calabria, Italy.
    Roselli M; Department of Systems Medicine, Medical Oncology, University Tor Vergata, Rome, Italy.
    Sanguineti G; Radiotherapy Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
    Sperduti I; Biostatistics Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
    Sapino A; Department of Medical Sciences, University of Turin, Turin, Italy.; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
    De Maria R; Institute of General Pathology, University Cattolica del Sacro Cuore, Rome, Italy.; Department of Medical Oncology, IRCCS Foundation University A. Gemelli, Rome, Italy.
    Leonetti C; Area of Translational Research, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
    Di Leo A; Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Prato, Italy.
    Ciliberto G; Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
    Falcioni R; Cellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
    Vici P; Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
    Pokaż więcej
    Źródło:
    Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2020 Dec 10; Vol. 39 (1), pp. 279. Date of Electronic Publication: 2020 Dec 10.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Biomarkers, Tumor/*metabolism
    Breast Neoplasms/*drug therapy
    Gene Expression Regulation, Neoplastic/*drug effects
    Receptor, ErbB-2/*antagonists & inhibitors
    Receptor, ErbB-2/*deficiency
    Ado-Trastuzumab Emtansine/administration & dosage ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Apoptosis ; Biomarkers, Tumor/genetics ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Cell Proliferation ; Female ; Humans ; Middle Aged ; Prognosis ; Retrospective Studies ; Survival Rate ; Trastuzumab/administration & dosage ; Tumor Cells, Cultured
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
    Autorzy:
    Ricciardi GRR; Medical Oncology Unit, A.O. Papardo & Department of Human Pathology University of Messina, Messina, Italy.
    Russo A; Medical Oncology Unit, A.O. Papardo & Department of Human Pathology University of Messina, Messina, Italy.
    Franchina T; Medical Oncology Unit, A.O. Papardo & Department of Human Pathology University of Messina, Messina, Italy.
    Schifano S; Medical Oncology Unit, A.O. Papardo & Department of Human Pathology University of Messina, Messina, Italy.
    Mastroeni G; Radiodiagnostic Unit, A.O. Papardo, Messina, Italy.
    Santacaterina A; Radiation Oncology Unit, A.O. Papardo, Messina, Italy.
    Adamo V; Medical Oncology Unit, A.O. Papardo & Department of Human Pathology University of Messina, Messina, Italy. .
    Pokaż więcej
    Źródło:
    BMC cancer [BMC Cancer] 2018 Jan 25; Vol. 18 (1), pp. 97. Date of Electronic Publication: 2018 Jan 25.
    Typ publikacji:
    Case Reports; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Brain Neoplasms/*drug therapy
    Breast Neoplasms/*drug therapy
    Maytansine/*analogs & derivatives
    Meningeal Neoplasms/*drug therapy
    Trastuzumab/*administration & dosage
    Ado-Trastuzumab Emtansine ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Brain Neoplasms/pathology ; Brain Neoplasms/radiotherapy ; Brain Neoplasms/secondary ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Breast Neoplasms/radiotherapy ; Combined Modality Therapy ; Docetaxel ; Female ; Humans ; Maytansine/administration & dosage ; Maytansine/adverse effects ; Meningeal Neoplasms/pathology ; Meningeal Neoplasms/radiotherapy ; Meningeal Neoplasms/secondary ; Middle Aged ; Receptor, ErbB-2/genetics ; Taxoids/administration & dosage ; Trastuzumab/adverse effects
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
    Autorzy:
    Santoni M; Department of Medical Oncology, AOU Ospedali Riuniti, Università Politecnica delle, Marche, Ancona, Italy. .
    Conti A; Department of Clinical and Specialist Sciences, Urology, Università Politecnica delle Marche, Ancona, Italy. .
    Procopio G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. .
    Porta C; Division of Medical Oncology, I.R.C.C.S. San Matteo University Hospital Foundation, Pavia, Italy. .
    Ibrahim T; Osteoncology and Rare Tumors Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, FC, Italy. .
    Barni S; Medical Oncology Department, Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, Italy. .
    Guida FM; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy. .
    Fontana A; Unit of Medical Oncology 2, Istituto Toscano Tumori, Azienda-Ospedaliero-Universitaria Pisana, Pisa, Italy. .
    Berruti A; Dipartimento di Specialità Medico-Chirurgiche, Medical Oncology, Scienze Radiologiche e Sanità Pubblica, Università degli Studi di Brescia, Azienda Ospedaliera Spedali Civili, Brescia, Italy. .
    Berardi R; Department of Medical Oncology, AOU Ospedali Riuniti, Università Politecnica delle, Marche, Ancona, Italy. .
    Massari F; Department of Medical Oncology, 'G.B. Rossi' Academic Hospital, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy. .
    Vincenzi B; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy. .
    Ortega C; Department of Medical Oncology, Institute for Cancer Research & Treatment (IRCC), Candiolo, Torino, Italy. .
    Ottaviani D; Department of Medical Oncology, Presidio Sanitario Gradenigo, Turin, Italy. .
    Carteni G; Department of Medical Oncology, Cardarelli Hospital, Naples, Italy. .
    Lanzetta G; Department of Neurological Sciences, Neuromed Institute, IRCSS, Pozzilli, IS, Italy. g_.; Istituto Neurotraumatologico Italiano, Unità Funzionale di Oncologia, Grottaferrata, Italy. g_.
    De Lisi D; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy. .
    Silvestris N; Medical Oncology Unit, National Cancer Research Centre 'Giovanni Paolo II', Bari, Italy. .
    Satolli MA; Department of Oncology, University of Turin, Medical Oncology 1, AOU Città della Salute e della Scienza, Turin, Italy. .
    Collovà E; Division of Medical Oncology, Hospital of Legnano, Milan, Italy. .
    Russo A; Department of Surgery and Oncology, Section of Medical Oncology, University of Palermo, Palermo, Italy. .
    Badalamenti G; Department of Surgery and Oncology, Section of Medical Oncology, University of Palermo, Palermo, Italy. .
    Luzi Fedeli S; Department of Medical Oncology, AOU Ospedali Riuniti, Università Politecnica delle Marche, Presidio San Salvatore, Pesaro, Italy. .
    Tanca FM; Department of Medical Oncology, University of Cagliari, Cagliari, Italy. .
    Adamo V; Department of Human Pathology, Medical Oncology Unit AOOR Papardo-Piemonte, University of Messina, Messina, Italy. .
    Maiello E; Oncology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy. .
    Sabbatini R; Dipartimento Integrato di Oncologia ed Ematologia, Medical Oncology Division, Università degli Studi di Modena e Reggio Emilia, Modena, Italy. .
    Felici A; Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy. .
    Cinieri S; Medical Oncology Department & Breast Unit - Hospital of Brindisi and Medical Oncology Department - European Institute of Oncology, Milan, Italy. .
    Montironi R; Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy. .
    Bracarda S; Department of Oncology, USL-8, Ospedale San Donato, Arezzo, Italy. .
    Tonini G; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy. .
    Cascinu S; Department of Medical Oncology, AOU Ospedali Riuniti, Università Politecnica delle, Marche, Ancona, Italy. .
    Santini D; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy. .
    Pokaż więcej
    Źródło:
    Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2015 Feb 05; Vol. 34, pp. 10. Date of Electronic Publication: 2015 Feb 05.
    Typ publikacji:
    Journal Article; Multicenter Study
    MeSH Terms:
    Bone Neoplasms/*mortality
    Bone Neoplasms/*secondary
    Carcinoma, Renal Cell/*mortality
    Carcinoma, Renal Cell/*pathology
    Kidney Neoplasms/*mortality
    Kidney Neoplasms/*pathology
    Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Survival Analysis
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study.
    Autorzy:
    Clavarezza M; Ospedale Sacro Cuore Don Calabria, Negrar, Verona, Italy. />Mustacchi G
    Casadei Gardini A
    Del Mastro L
    De Matteis A
    Riccardi F
    Adamo V
    Aitini E
    Amoroso D
    Marchetti P
    Gori S
    Carrozza F
    Maiello E
    Giotta F
    Dondi D
    Venturini M
    Pokaż więcej
    Źródło:
    BMC cancer [BMC Cancer] 2012 Jun 06; Vol. 12, pp. 216. Date of Electronic Publication: 2012 Jun 06.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Biomarkers, Tumor/*metabolism
    Breast Neoplasms/*metabolism
    Breast Neoplasms/*pathology
    Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/drug therapy ; Chemotherapy, Adjuvant ; Female ; Humans ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study.
    Autorzy:
    Pergolizzi S; Department of Radiological Science, University of Messina, Messina, Italy.
    Santacaterina A
    Adamo B
    Franchina T
    Denaro N
    Ferraro P
    Ricciardi GR
    Settineri N
    Adamo V
    Pokaż więcej
    Źródło:
    Radiation oncology (London, England) [Radiat Oncol] 2011 Nov 22; Vol. 6, pp. 162. Date of Electronic Publication: 2011 Nov 22.
    Typ publikacji:
    Clinical Trial; Journal Article
    MeSH Terms:
    Carcinoma, Squamous Cell/*therapy
    Chemoradiotherapy/*methods
    Head and Neck Neoplasms/*therapy
    Induction Chemotherapy/*methods
    Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Squamous Cell/pathology ; Cisplatin/administration & dosage ; Female ; Head and Neck Neoplasms/pathology ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Paclitaxel/administration & dosage ; Prospective Studies
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-9 z 9

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies